News

Science Daily22h
AI algorithm can help identify high-risk heart patients to quickly diagnose, expedite, and improve care
Mount Sinai researchers studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) have calibrated an artificial intelligence (AI) algorithm to quickly and more specifically identify ...
News-Medical.Net on MSN3d
Mount Sinai researchers enhance AI tool to better detect heart disease risk
Mount Sinai researchers studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) have calibrated an artificial intelligence (AI) algorithm to quickly and more specifically identify ...
AI algorithm can help identify high-risk heart patients: Study
A team of US researchers, studying a type of heart disease known as hypertrophic cardiomyopathy (HCM), on Tuesday said they ...
BioPharma Dive10d
Bristol Myers stumbles in bid to widen heart drug’s use
Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...
Clinical Trials Arena on MSN9d
BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial
BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...
Mirage News3d
AI Tool Speeds Diagnosis for High-Risk Heart Patients
Mount Sinai researchers studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) have calibrated an artificial intelligence (AI ...
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) ...